

Novel Synthesis of New Triazine Sulfonamides with Antitumor, Antimicrobial and Anti-SARS-CoV-2 Activities

Reham A. Mohamed-Ezzat

National Research Center

galal elgemeie

elgemeie@yahoo.com

Helwan University

Research Article

Keywords: Anti-Microbial; anti-proliferative, SARS-CoV-2, triazines, sulfonamides; Synthesis.

Posted Date: January 22nd, 2024

DOI: <https://doi.org/10.21203/rs.3.rs-3862708/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: No competing interests reported.

Version of Record: A version of this preprint was published at BMC Chemistry on March 26th, 2024. See the published version at <https://doi.org/10.1186/s13065-024-01164-9>.

Novel Synthesis of New Triazine Sulfonamides with Antitumor, Antimicrobial and Anti-SARS-CoV-2 Activities

Reham A. Mohamed-Ezzat^a & Galal H. Elgemeie^{b*}

^aChemistry of Natural & Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Center, Cairo, 12622, Egypt. ^bDepartment of Chemistry, Faculty of Science, Helwan University, Cairo, 11795, Egypt.

Corresponding email: elgemeie@yahoo.com

Abstract

Novel approach for synthesizing triazine sulfonamide derivatives is accomplished via reacting the sulfaguanidine derivatives with *N*-cyanodithioiminocarbonate. Further reaction of the novel triazine sulfonamide analogues were reacted with various secondary amines, anilines and 2-aminothiazole to generate various substituted triazine sulfonamide analogues of promising broad spectrum activities. The in vitro anti-proliferative activities of most of the novel compounds were evaluated on the NCI-60 cell line panel. The antifungal and antibacterial activities of the compounds were also estimated. The antiviral activity against SARS COV-2 virus was performed to evaluate the half-maximal cytotoxic concentration (CC₅₀) and inhibitory concentration 50 (IC₅₀) of a representative compound from the novel triazine sulfonamide category.

KeyWords


Anti-Microbial; anti-proliferative, SARS-CoV-2, triazines, sulfonamides; Synthesis.

1. Introduction

Numerous antibiotics and other antimicrobials have been developed. However, the threat raised by antimicrobial resistance (AMR) is more recent and requires immediate attention [1, 2]. Recent years have seen a significant increase in antibiotic resistance on a global level. Almost seventeen million people die every year from infectious diseases, especially bacterial infections [3]. Many commercially available antibiotics are considered to be ineffective for treating microorganisms that have developed resistance to them [4]. Antibiotic resistance is a problem that has been related to antibiotic overuse, abuse, and a lack of new efficient drugs. Bacteria are considered major, urgent, and alarming concerns by the Centres for Disease Control and Prevention (CDC), many of which have a significant clinical and economic impact on the global population [5]. Due to the rapid increase in resistance to currently accessible, commercially

available antibiotics, it is imperative to develop novel antibacterial treatments with increased action to combat drug-resistant conditions [6].

Many sulfonamides are known to be effective as antimicrobial drugs such as silver sulfadiazine (fig.1) (*Flamazine*, *Silvadene*, *Ssd*, *Thermazene*) which is a topical sulfonamide antibiotic that acts on the bacterial cell wall and cell membrane; approved for treating burns [7].






Fig. 1. Potent sulfonamides & Triazines and our novel design of the triazine sulfonamides.

Sulfathiazole (fig.1) is a short-acting sulfa drug, was a widely used oral and topical antimicrobial until less toxic alternatives were discovered. The use of it is still sporadic, occasionally in combination with sulfacetamide and sulfabenzamide [8]. A sulfonamide antibiotic called Sulfamethizole (Brand Name: *Urobiotic*) (fig.1) is used to treat a wide range of susceptible bacterial infections [9].

In order to address drug resistance concerns and to treat opportunistic microbial infections, researchers have reported triazine core molecules displaying high antimicrobial potency in terms of antifungal and antibacterial. To fight against human disease-causing pathogens [10-12], thiazole-triazines [13, 14], quinoline-triazine core [15, 16], quinazoline-triazine derivatives [17], coumarinyl-triazine derivatives [18], fullerene-based triazine compounds [19], disubstituted-s-triazines [20], tri-substituted s-triazine [21], s-triazine nucleobases [22], and many other s-triazine derivatives [23, 24].

The sulfonamide moiety has attracted a lot of interest in medicinal chemistry, as a number of sulfonamides have been synthesized with a varied range of biological activities, including anti-fungal, anti-bacterial, anti-oxidant, anti-diabetic, anti-inflammatory [25], and anti-cancer

potencies [25-32]. Among them, the FDA has approved various sulfonamide derivatives for use in cancer therapy [25].


Herein, we have synthesized novel triazines sulfonamides utilizing dimethyl *N*-cyanodithioiminocarbonate which is considered as an important compound used in the synthesis of various biologically active heterocycles [33, 34], noteworthy, we have previously used this active reagents in synthesizing many novel antimetabolite analogues [35-40].

2. Results and discussion

2.1. Chemistry

The reaction of the substituted sulfaguanidine **1** with *N*-cyanodithioiminocarbonate **2** furnished the novel analogues of the triazine sulfonamide **3**. Cyclization of arylsulfonyl guanidine **1a-d** with compound **2** occurs in the presence of potassium hydroxide in dioxane under reflux to afford the targeted products **3a-c** (Scheme 1). The ¹H NMR spectrum of compound **3a** revealed the presence of a singlet signal δ 2.29 ppm for the three protons of the methythio group, singlet at δ 7.35 for the NH₂ Protons, and in the range from δ 7.54 to δ 7.98 ppm the aromatic protons were detectable, additionally the NH protons was appeared at δ 11.83 ppm. The structure of the compound is confirmed via single X-ray diffraction analysis as depicted in figure 2 [41].

Further reaction of the latter compounds with sec. amines such as morpholine, piperidine, *N*-methyl piperazine in the presence of potassium carbonate in refluxing dioxane furnishes the substituted triazine sulfonamides **4**. Additionally, the reaction of compound **3** with pyrrolidine generated compound **5**. The desired compounds were characterized using spectral and elemental analysis. The ¹H NMR spectrum of compound **5a** revealed the presence of four multiplet signals at δ 1.76. ppm, two multiplet signals at δ 3.2 ppm, and two multiplet signals at δ 3.34ppm of the methylene groups of the pyrrolidine moiety. Owing to the NH₂ signal, it was appeared at δ 6.82 ppm, also the aromatic signals appeared at the range from δ 7.43 to δ 7.87 ppm, and the NH proton of the sulfonamide group was appeared at δ 11.19 ppm. In order to investigate the scope of this approach the triazine sulfonamides was reacted with aniline derivatives to afford a general methodology to the substituted triazine sulfonamides **7** (Scheme 2).



1, 3, 5 R
 a; H
 b; Cl
 c; NHCOCH₃

4 R X
 a; H CH₂
 b; H O
 c; Cl O
 d; Cl N-CH₃

Reagents and conditions: i) Dioxane, potassium hydroxide, reflux, 2h. ii) Dioxane, amine, potassium carbonate, reflux, 2h. iii) Dioxane, pyrrolidine, potassium carbonate, reflux, 2h.

Scheme 1





Figure 2. The molecule of Structure **3a** in the crystal.

“The figure is reproduced via permission of the International Union of Crystallography under the open-access licence” [41].



Reagents and conditions: i) Dioxane, potassium carbonate, reflux, 2h.

Scheme 2

2.2 Biological activity

2.2.1. *In-vitro* Anti-proliferative activity

Estimation of in vitro antiproliferative activity was performed on the NCI-60 cell line panel. The US NIH's National Cancer Institute ("NCI") has selected the majority of structures for its Developmental Therapeutic Program (DTP). Various human tumor cell lines are used in screening procedures, including cell lines expressing brain, melanoma, leukemia, lung, ovarian, colon, kidney, prostate and breast malignancies.

The NCI screening process favors compounds with drug-like mechanisms of action according to computer-aided design. Whether the submitted compounds can diversify the NCI collection of small molecule compounds will govern which ones will be utilized for subsequent screening.

The compounds that have been elected were tested on the NCI cell panel and assumed the consistent NCI codes NSC D-840972, NSC D-840973, NSC D-D-840979, NSC D-840978, NSC D-840977, NSC D-840975, NSC D-840976, & NSC D-840980 to signify the diverse structures of this research. For each compound on each NCI cell line, the effects are expressed as a percentage of cell growth.

The lowest cell growth promotion for compound **3a** was against leukemia RPMI-8226 cell line (GP = 104.02%), non-small cell lung cancer EKVX cell line (GP = 77.46%), colon cancer HCT-15 cell line (GP = 96.34%), CNS cancer SNB-75 (GP = 74.76%), melanoma SK-MEL-5 (GP = 72.98%), ovarian cancer OVCAR-4 (GP = 95.65%), renal cancer CAKI-1 (GP = 88.61%), prostate cancer PC-3 (GP = 103.05%), and breast cancer MCF7 (GP = 84.02%). Compound **3b** displayed the lowest cell growth promotion against leukemia HL-60(TB) cell line (GP = 90.58%), non-small cell lung cancer EKVX cell line (GP = 80.79%), colon cancer HCT-15 cell line (GP = 97.17%), CNS cancer SNB-75 (GP = 77.59%), melanoma MALME-3M (GP = 84.52%), ovarian cancer OVCAR-4 (GP = 91.13%), renal cancer CAKI-1 (GP = 81.13%), prostate cancer DU-145 (GP = 107.83%), and breast cancer MCF7 (GP = 87.47%).

Additionally, the lowest cell growth promotion for compound **4a** was against leukemia K-562 cell line (GP = 98.62%), non-small cell lung cancer HOP-92 cell line (GP = 89.70%), colon cancer HCT-15 cell line (GP = 97.79%), CNS cancer SNB-75 (GP = 77.71%), melanoma SK-MEL-5 (GP = 92.87%), ovarian cancer OVCAR-4 (GP = 86.36%), renal cancer UO-31 (GP = 85.43%), prostate cancer PC-3 (GP = 106.53%), and breast cancer MCF7 (GP = 93.45%). Alongside compound **4b** showed the lowest cell growth promotion against leukemia SR cell line (GP = 87.88%), non-small cell lung cancer EKVX cell line (GP = 90.00%), colon cancer HCT-15 cell line (GP = 99.61%), CNS Cancer SNB-75 (GP = 78.73%), melanoma UACC-62 (GP = 94.30%), ovarian cancer OVCAR-4 (GP = 90.71%), renal cancer CAKI-1 (GP = 89.24%), prostate cancer DU-145 (GP = 113.40%), and breast cancer MCF7 (GP = 91.47%).

The lowest cell growth promotion for compound **5a** was against leukemia SR cell line (GP = 90.10%), non-small cell lung cancer EKVX cell line (GP = 80.80%), colon cancer HCT-116 cell line (GP = 98.89%), CNS cancer SNB-75 (GP = 75.30%), melanoma UACC-62 (GP = 80.87%), ovarian cancer OVCAR-4 (GP = 83.44%), renal cancer UO-31 (GP = 81.59%), prostate cancer PC-3 (GP = 91.32%), and breast cancer MDA-MB-231/ATCC (GP = 88.39%). Meanwhile, compound **5b** exhibited the lowest cell growth promotion against leukemia HL-60(TB) cell line (GP = 93.23%), non-small cell lung cancer EKVX cell line (GP = 80.41%), colon cancer HCT-116 cell line (GP = 95.84%), CNS cancer SNB-75 (GP = 77.45%),

melanoma UACC-62 (GP = 87.29%), ovarian cancer OVCAR-4 (GP = 85.99%), renal cancer CAKI-1 (GP = 86.60%), prostate cancer DU-145 (GP = 105.36%), and breast cancer MCF7 (GP = 86.42%).

Furthermore the lowest cell growth promotion for compound **7b** was against leukemia HL-60(TB) cell line (GP = 78.31%), non-small cell lung cancer EKVX cell line (GP = 92.73%), colon cancer HCT-15 cell line (GP = 98.79%), CNS cancer SNB-75 (GP = 81.18%), melanoma SK-MEL-5 (GP = 87.34%), ovarian cancer OVCAR-4 (GP = 94.63%), renal cancer CAKI-1 (GP = 87.08%), prostate cancer DU-145 (GP = 108.61%), and breast cancer MCF7 (GP = 97.13%).

In conclusion it is remarkable that compound **3a** the most potent among the estimated compounds, revealed remarkably lowest cell growth promotion against melanoma SK-MEL-5 (GP = 72.98%), CNS cancer SNB-75 (GP = 74.76%), and non-small cell lung cancer EKVX cell line (GP = 77.46%). Compound **7b** showed the lowest cell growth promotion against leukemia HL-60(TB) cell line (GP = 78.31%), **3b** renal cancer CAKI-1 (GP = 81.13%). Compound **5a** revealed the lowest cell growth promotion against ovarian cancer OVCAR-4 (GP = 83.44%), prostate cancer PC-3 (GP = 91.32%), and breast cancer MDA-MB-231/ATCC (GP = 88.39%). Additionally compound **5b** showed the lowest cell growth promotion against colon cancer HCT-116 cell line (GP = 95.84%).

Table 1. Anti-tumor properties of the compounds at a dose of 10 μ M using human tumor cell lines

Panel/Cell line	3a	3b	4a	4b	5a	5b	7b
Leukemia							
CCRF-CEM	109.88	100.29	116.66	106.84	96.89	116.52	116.17
HL-60(TB)	112.07	90.58	114.70	114.78	109.12	93.23	78.31
K-562	104.72	91.75	98.62	97.56	92.02	95.72	88.84
MOLT-4	108.90	99.31	98.73	103.63	107.38	99.53	95.99
RPMI-8226	104.02	105.57	100.08	113.68	92.47	99.37	107.97
SR	117.75	98.34	105.41	87.88	90.10	106.56	103.56
Non-Small cell Lung cancer							
A549/ATCC	98.66	98.81	105.02	105.10	105.57	105.50	103.59
EKVX	77.46	80.79	90.29	90.00	80.80	80.41	92.73
HOP-62	85.52	93.97	95.69	98.70	96.56	97.94	102.04
HOP-92	122.02	129.24	89.70	117.23	96.50	91.06	118.08
NCI-H226	93.04	94.32	94.39	98.66	86.85	95.95	96.79
NCI-H23	103.76	94.93	96.92	102.47	92.18	98.55	105.42
NCI-H322M	101.09	98.60	102.91	96.07	99.63	97.47	104.87
NCI-H460	103.67	103.16	103.61	102.31	100.92	100.37	102.22
NCI-H522	98.70	86.83	98.57	93.50	85.01	93.04	94.94
Colon cancer							
COLO 205	109.77	117.05	107.26	108.68	104.06	109.34	109.93
HCC-2998	108.67	120.78	110.46	108.19	103.14	110.53	111.51
HCT-116	99.60	100.28	99.11	101.85	98.89	95.84	102.90
HCT-15	96.34	97.17	97.79	99.61	101.80	100.44	98.79
HT29	108.29	116.29	105.23	102.68	104.11	109.46	112.65
KM12	106.63	106.43	109.05	104.54	102.17	101.19	104.16

SW-620	105.70	100.74	101.32	106.70	99.76	98.98	105.00
CNS Cancer							
SF-268	96.54	98.96	101.29	103.77	95.21	96.49	99.36
SF-295	90.83	86.82	93.19	93.07	86.80	90.82	97.23
SF-539	101.08	92.86	97.24	97.97	89.91	95.16	92.58
SNB-19	98.77	95.13	95.81	95.83	90.09	97.19	95.53
SNB-75	74.76	77.59	77.71	78.73	75.30	77.45	81.18
U251	103.95	99.30	104.64	107.53	97.45	107.68	99.84
Melanoma							
LOX IMVI	95.77	94.66	98.93	97.31	89.29	97.71	94.31
MALME-3M	97.44	84.52	101.06	100.69	93.92	91.01	102.01
M14	102.37	101.94	104.95	98.91	101.13	100.91	99.60
MDA-MB-435	100.60	101.75	98.30	98.72	99.57	100.87	99.48
SK-MEL-2	128.41	102.83	112.24	105.73	116.13	110.65	111.32
SK-MEL-28	99.39	101.04	103.77	101.19	96.01	95.97	97.92
SK-MEL-5	72.98	106.78	92.87	95.62	85.03	95.30	87.34
UACC-257	99.97	103.60	102.15	103.01	111.28	105.19	105.56
UACC-62	103.11	84.71	94.57	94.30	80.87	87.29	94.38
Ovarian cancer							
IGROV1	103.94	97.31	110.12	106.47	100.49	89.71	107.05
OVCAR-3	114.38	110.36	106.76	112.06	105.84	106.71	108.62
OVCAR-4	95.65	91.13	86.36	90.71	83.44	85.99	94.63
OVCAR-5	104.49	100.03	103.05	100.77	96.50	91.37	99.69
OVCAR-8	104.22	101.58	104.63	106.02	103.10	101.58	105.11

NCI/ADR-RES	100.60	99.63	103.92	102.27	99.25	101.70	100.28
SK-OV-3	103.08	91.32	107.02	113.01	93.62	98.21	101.24
Renal Cancer							
786-0	103.15	108.31	110.30	102.34	100.37	101.72	99.30
A498	101.04	110.05	115.02	105.58	103.47	112.37	98.23
ACHN	99.94	98.49	102.14	101.60	91.57	101.12	102.62
CAKI-1	88.61	81.13	92.13	89.24	83.53	86.60	87.08
RXF 393	118.89	105.80	102.59	101.71	90.00	105.38	104.55
SN12C	101.86	96.10	96.05	98.77	85.63	95.34	100.37
TK-10	101.71	134.03	104.72	93.71	107.73	125.56	104.11
UO-31	92.40	81.52	85.43	89.82	81.59	89.98	92.55
Prostate Cancer							
PC-3	103.05	112.09	106.53	113.83	91.32	107.65	115.88
DU-145	106.44	107.83	109.84	113.40	109.35	105.36	108.61
Breast Cancer							
MCF7	84.02	87.47	93.45	91.47	90.37	86.42	97.13
MDA-MB-231/ATCC	98.98	90.59	100.13	93.08	88.39	92.68	104.60
HS 578T	99.34	97.30	107.63	113.10	93.30	99.61	111.99
BT-549	104.79	106.72	110.89	109.75	99.59	98.36	105.65
T-47D	94.87	92.07	93.59	98.98	91.58	95.54	99.03

2.2.2. Antimicrobial evaluation

Most of the novel compounds were estimated for their *in vitro* anti-bacterial efficacy against some species of Gram (–ve) bacteria, namely, *Escherichia coli*, *Klebsiella pneumonia*, and *Pseudomonas aeruginosa*, along with two Gram (+ve) bacteria, namely, *Staphylococcus aureus* and *Streptococcus mutans*.

Additionally, their effectiveness against the fungus *Candida albicans* was assessed. To estimate the preliminary anti-bacterial and anti-fungal potencies, the agar-diffusion method was utilized.

Nystatin, Ampicillin, and Gentamicin were also used as standard drugs against fungal, Gram +ve bacterial, and Gram –ve bacterial strains, respectively. The reports of the antimicrobial results were expressed as the average diameter of inhibition zones of the microbial growth around the disks in mm values, as accomplished in table 2.

As depicted in table 2, compound **4a** showed some activities against the gram negative bacterial strain, *Escherichia coli* (ATCC:10536) (inhibition zone 11.6 ± 0.6 mm) compared to Gentamicin (inhibition zone 27 ± 1.0 mm), while revealing inhibition zone against the gram positive strain, *Staphylococcus aureus* (ATCC:13565) (inhibition zone 11.3 ± 0.6 mm), when compared to Ampicillin (inhibition zone 21.7 ± 0.6 mm). Its worthy to note that no apparent potency was observed for compound **4a** against the fungal strain *Candida albicans* (ATCC:10231) compared to Nystatin (inhibition zone 21 ± 1.0 mm). On the other hand compound **3c** showed fungal zone of inhibition with the value 13.3 ± 0.6 mm against the *Candida albicans* (ATCC:10231) compared to Nystatin (inhibition zone 21 ± 1.0 mm). Thus, **3c** is considered as the most potent compound with antifungal activity among the other tested compounds. Compound **5a** indicated inhibition zone against the gram positive strain, *Staphylococcus aureus* (ATCC:13565) (inhibition zone 11.6 ± 0.6 mm).

Compound **3a** & **5a** revealed fungal zone of inhibition with the value 12.3 ± 0.6 mm, and 9.6 ± 0.6 , respectively against the *Candida albicans* (ATCC:10231) compared to Nystatin. Compound **7b** is considered is the only compound among the examined ones which revealed potency against the *Pseudomonas aeruginosa* (ATCC:27853) with inhibition zone value of 11.3 ± 0.6 respectively.

Against gram positive bacteria *Staphylococcus aureus* (ATCC:13565) compound **4d** indicated bacterial zone of inhibition with the value of 9.3 ± 0.6 mm. The activity of the **5b** against the gram positive bacteria *Staphylococcus aureus*, and *Streptococcus mutans* with inhibition zone value of 9.6 ± 0.6 , & 10.3 ± 0.6 respectively. All the tested compounds revealed no apparent potency against *Klebsiella pneumonia* (ATCC:10031).

Table 2. Determination of the antimicrobial activity of compounds (**3a**, **3b**, **3c**, **4a**, **4b** and **4c**) against different antibacterial and fungal strains.

Sample Microorganism	3a	3b	3c	4a	4b	4c	Standard antibiotic
Gram negative bacteria							Gentamicin
<i>Escherichia coli</i> (ATCC:10536)	NA	NA	NA	11.6± 0.6	NT	NA	27±1.0
<i>Klebsiella pneumonia</i> (ATCC:10031)	NA	NT	NA	NT	NT	NA	25±1.0
<i>Pseudomonas aeruginosa</i> (ATCC:27853)	NA	NT	NA	NT	NT	NA	27.3±0.6
Gram positive bacteria							Ampicillin
<i>Staphylococcus aureus</i> (ATCC:13565)	NA	NA	NA	11.3± 0.6	NA	NA	21.7±0.6
<i>Streptococcus mutans</i> (ATCC:25175)	NA	NA	NA	NA	NA	NA	30±1.0
Fungi							Nystatin
<i>Candida albicans</i> (ATCC:10231)	12.3± 0.6	NA	13.3±0. 6	NA	NA	NA	21±1.0

Table 3. Determination of the antimicrobial activity of compounds (**4d**, **5a**, **5b**, and **7b**) against different antibacterial and fungal strains.

Sample Microorganism	4d	5a	5b	7b	Standard antibiotic
Gram negative bacteria					Gentamicin
<i>Escherichia coli</i> (ATCC:10536)	NT	NA	NA	NA	27±1.0
<i>Klebsiella pneumonia</i> (ATCC:10031)	NT	NA	NA	NA	25±1.0
<i>Pseudomonas aeruginosa</i> (ATCC:27853)	NT	NA	NT	11.3± 0.6	27.3±0.6
Gram positive bacteria					Ampicillin
<i>Staphylococcus aureus</i> (ATCC:13565)	9.3± 0.6	11.6± 0.6	9.6±0. 6	NA	21.7±0.6
<i>Streptococcus mutans</i> (ATCC:25175)	NA	NA	10.3±0 .6	NA	30±1.0
Fungi					Nystatin
<i>Candida albicans</i> (ATCC:10231)	NA	9.6± 0.6	NA	NA	21±1.0

2.2.3. SARS-COV-2.

The novel synthesized compound **3a** was evaluated for its anti-viral potency against SARS COV-2 virus to determine the half-maximal cytotoxic concentration (CC_{50}) and inhibitory concentration 50 (IC_{50}). The result of the MTT assay revealed that compound **3a** has high and potent antiviral activity against SARS-CoV-2. The antiviral activity of the compound is identified with $IC_{50}= 2.37$ and $CC_{50}=577.2$ (Fig. 3).




Fig. 3. Graph of inhibitory concentration 50 (IC_{50}) of tested compound **3a**: Antiviral activity against SARS-CoV-2.

Conclusion

In conclusion, the synthesis of triazine sulfonamides and its analogues were achieved starting from sulfaguanidine derivatives. Our synthetic approach is expected to contribute the provision of a wide range of triazine sulfonamide analogs starting from the crucial intermediate *N*-cyanodithioiminocarbonate. The insertion of several amines or aryl groups yielded the novel substituted triazine sulfonamides. The in vitro anti-proliferative activities, the antimicrobial activities and the antiviral activity against SARS-COV-2 virus were showed promising results for developing these novel structures. Further studies concerning

synthesizing other triazine sulfonamide analogs and the evaluation of their biological potency are currently in progress.

3. Experimental

3.1 Methods. On the pre-coated silica gel 60 F245aluminum plates, TLC was utilized for monitoring the reaction's development and the UV light was used for visualisation. The Stuart SMP30 equipment was used to determine the melting point that was uncorrected. In the faculty of Pharmacy at the Drug Discovery, Research & Development Centre at Ain Shams University and in the National Research Center, Egypt, the spectroscopic analyses of the compounds was carried out. On Bruker Fourier 400 & 500 (operating at 400 MHz & 500 MHz, respectively) at 300 K, the NMR spectra were measured. The National Cancer Institute in Bethesda, Maryland, United States, conducted the anticancer screening. Antimicrobial evaluation carried out at the Cairo University's Faculty of Science's Microbiology Unit in the Biochemistry Central Lab, Cairo, Egypt. The Centre of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Cairo 12622, Egypt, conducted the antiviral assays for the SARS-COV-2 virus.

3.1. Synthesis

3.1.1. Synthesis of N-[3,4-dihydro-4-amino-6-(methylthiol)triazin-2-yl]benzenesulfonamide derivatives 3.

General procedure I:

A mixture of substituted sulfaguanidine **1** (0.01 mol) with *N*-cyanodithioiminocarbonate **2** (0.01 mol) in dry dioxane (20 mL) containing potassium hydroxide (0.015 mol) was refluxed for 3 h. The reaction mixture was poured into ice-water, filtered, washed thoroughly with water, dried and crystallized from ethanol to obtain the desired product.

3.1.1.1. Synthesis of N-[3,4-dihydro-4-amino-6-(methylthiol)triazin-2-yl]benzenesulfonamide

(3a).

According to general procedure I, compound **2** reacted with benzenesulfonylguanidine (**1a**) to afford compound **3a** as an off white solid (87 %); mp 247-249 °C; IR (KBr, cm⁻¹): ν 3261, 3202 (NH), 3065 (Ar-CH), 2931, 2813 (alph. CH), 1555 (C=C), 1358, 1141 (SO₂); ¹H NMR (400 MHz, DMSO-*d*₆): δ 2.29 (s, 3H, CH₃), 7.35 (s, 2H, NH₂), 7.54-7.64 (m, 3H, Ar-H), 7.96-7.98 (d, 2H, Ar-H), 11.83 (s, 1H, NH); ¹³C-

NMR (400 MHz, DMSO- d_6) δ (ppm): 12.53, 127.75, 128.75, 132.79, 140.85, 159.76, 163.42, 180.34. Anal. Calcd. For. $C_{10}H_{11}N_5O_2S_2$ (297.36): C, 40.39; H, 3.73; N, 23.55; S, 21.57. Found: C, 40.38; H, 3.72; N, 23.55; S, 21.56.

3.1.1.2. Synthesis of *N*-[3,4-dihydro-4-amino-6-(methylthiol)triazin-2-yl]-4-chlorobenzenesulfonamide (3b).

According to general procedure I, compound **2** reacted with *p*-chlorobenzenesulfonylguanidine (**1b**) to afford compound **3b** as an off white solid (84%); mp 283-285 °C; IR (KBr, cm^{-1}): ν 3455, 3260, 3201 (NH), 2980 (alph. CH), 1555 (C=C), 1359, 1141 (SO₂); ¹H NMR (400 MHz, DMSO- d_6): δ 2.49 (s, 3H, CH₃), 7.41 (s, 1H, NH), 7.60-7.62 (d, 2H, Ar-H), 7.74 (s, 1H, NH), 7.94-7.97 (d, 2H, Ar-H), 11.79 (s, 1H, NH); ¹³C-NMR (400 MHz, DMSO- d_6) δ (ppm): 12.50, 128.70, 129.70, 137.33, 140.05. Anal. Calcd. For. $C_{10}H_{10}ClN_5O_2S_2$ (331.8): C, 36.20; H, 3.04; Cl, 10.68; N, 21.11; S, 19.33. Found: C, 36.20; H, 3.03; Cl, 10.67; N, 21.11; S, 19.32.

3.1.1.3. Synthesis of *N*-[3,4-dihydro-4-amino-6-(methylthiol)triazin-2-yl]-4-acetamidobenzenesulfonamide (3c).

According to general procedure I, compound **2** reacted with *p*-acetamidobenzenesulfonylguanidine (**1c**) to afford compound **3c** as a brown solid (40 %); mp >340 °C; ¹H NMR (400 MHz, DMSO- d_6): δ ¹H NMR (400 MHz, DMSO- d_6): δ 2.41 (s, 3H, CH₃), 2.49 (s, 3H, CH₃), 7.00 (s, 1H, NH), 7.26 (s, 1H, NH₂), 7.27-7.29 (d, 2H, Ar-H), 7.51-7.53 (d, 2H, Ar-H), 7.91 (s, 1H, NH), 8.68 (s, 1H, NH); Anal. Calcd. For. $C_{12}H_{14}N_6O_3S_2$ (354.41): C, 40.67; H, 3.98; N, 23.71; S, 18.09. Found: C, 40.67; H, 3.97; N, 23.70; S, 18.08.

3.1.2. Synthesis of substituted *N*-[3,4-dihydro-4-amino-6-(methylthiol)triazin-2-yl]benzenesulfonamides 4, 5, and 7.

General procedure II:

A mixture of *N*-[3,4-dihydro-4-amino-6-(methylthiol)triazin-2-yl]benzenesulfonamide (0.01 mol) with various secondary amines (0.02 mol), or anilines **7** (0.01 mol) in dry dioxane (20 mL) containing potassium carbonate (0.015 mol) was refluxed for 3 h. The reaction mixture was poured into ice-water, filtered, washed thoroughly with water, dried and crystallized from ethanol to obtain the desired product.

3.1.2.1. Synthesis of *N*-[3,4-dihydro-4-amino-6-(piperidin-1-yl)triazin-2-yl]benzenesulfonamide (4a).

According to general procedure II, compound **3** reacted with piperidine to afford compound **5a** as a buff solid (62 %); mp 319-320 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ 1.30 (m, 2H, CH₂), 2.49 (m, 4H, CH₂), 3.62 (m, 4H, CH₂), 6.13 (s, 2H, NH₂), 7.31-7.35 (m, 1H, Ar-H), 7.37-7.44 (m, 2H, Ar-H), 7.76-7.78 (m, 1H, Ar-H), 7.86-7.89 (d, 1H, Ar-H), 9.53 (s, 1H, NH); Anal. Calcd. For. C₁₄H₁₈N₆O₂S (334.4): C, 50.28; H, 5.43; N, 25.13; S, 9.59. Found: C, 50.27; H, 5.43; N, 25.12; S, 9.58.

3.1.2.2. Synthesis of *N*-[3,4-dihydro-4-amino-6-morpholinotriazin-2-yl]benzenesulfonamide (4b).

According to general procedure II, compound **3a** reacted with morpholine to afford compound **4b** as an off white solid (73 %); mp 360-363 °C; IR (KBr, cm⁻¹): ν 2985(Ar-CH), 2972, 2907, 2873, 2850 (alph. CH), 1550 (C=C), 1357, 1135 (SO₂); ¹H NMR (400 MHz, DMSO-*d*₆): δ 2.62 (m, 2H, CH₂), 3.11 (m, 2H, CH₂), 3.47 (m, 4H, CH₂), 5.67 (s, 1H, NH), 6.09 (s, 2H, NH₂), 7.31 (m, 3H, Ar-H), 7.70 (m, 1H, Ar-H), 7.76 (m, 1H, Ar-H); Anal. Calcd. For. C₁₃H₁₆N₆O₃S (336.37): C, 46.42; H, 4.79; N, 24.98; S, 9.53. Found: C, 46.42; H, 4.79; N, 24.97; S, 9.52.

3.1.2.3. Synthesis of *N*-[3,4-dihydro-4-amino-6-morpholinotriazin-2-yl]-4-chlorobenzenesulfonamide (4c).

According to general procedure II, compound **3b** reacted with morpholine to afford compound **4c** as off white solid (81 %); mp 342-343 °C; Anal. Calcd. For. C₁₃H₁₅ClN₆O₃S (370.81): C, 42.11; H, 4.08; Cl, 9.56; N, 22.66; S, 8.65. Found: C, 42.11; H, 4.07; Cl, 9.55; N, 22.66; S, 8.64.

3.1.2.4. Synthesis of *N*-[3,4-dihydro-4-amino-6-(4-methylpiperazin-1-yl)-triazin-2-yl]-4-chlorobenzenesulfonamide (4d).

According to general procedure II, compound **3b** reacted with 4-methylpiperazine to afford compound **4d** as a buff solid (51 %); mp 270-273 °C; Anal. Calcd. For. C₁₄H₁₈ClN₇O₂S (383.86): C, 43.81; H, 4.73; Cl, 9.24; N, 25.54; S, 8.35. Found: C, 43.81; H, 4.73; Cl, 9.23; N, 25.53; S, 8.34.

3.1.2.5. Synthesis of *N*-[3,4-dihydro-4-amino-6-(pyrrolidin-1-yl)triazin-2-yl]benzenesulfonamide (5a).

According to general procedure II, compound **3a** reacted with pyrrolidine to afford compound **5a** as buff crystals (81 %); mp 317 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ 1.76 - 1.77 (m, 4H, CH₂); 3.20 - 3.23 (m, 2H, CH₂), 3.32 - 3.36 (m, 2H, CH₂), 6.82 (s, 2H, NH₂), 7.43-7.50 (m, 2H, Ar-H), 7.84-7.87 (d, 2H, Ar-H), 7.97-7.99 (d, 1H, Ar-H), 11.19 (s, 1H, NH); ¹³C-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 12.87, 24.95, 25.03, 46.80, 46.97, 127.66, 128.13, 129.11, 131.26, 144.42. Anal. Calcd. For. C₁₃H₁₆N₆O₂S (320.37): C, 48.74; H, 5.03; N, 26.23; S, 10.01. Found: C, 48.74; H, 5.02; N, 26.22; S, 10.00.

3.1.2.6. Synthesis of *N*-[3,4-dihydro-4-amino-6-(pyrrolidin-1-yl)triazin-2-yl]-4-chlorobenzenesulfonamide (5b).

According to general procedure II, compound **3b** reacted with pyrrolidine to afford compound **5b** as a buff solid (78 %); mp 237 °C; IR (KBr, cm⁻¹): ν 3346, 3209 (NH), 2971 (Ar-CH), 2873 (alph. CH), 1541 (C=C), 1390, 1132 (SO₂); ¹H NMR (400 MHz, DMSO-*d*₆): δ 1.76 (m, 2H, CH₂); 1.82-1.85 (m, 2H, CH₂), 3.13 - 3.21 (m, 4H, CH₂), 5.79 (s, 1H, NH), 6.17 (s, 1H, NH₂), 6.61 (s, 1H, NH), 7.34-7.40 (m, 2H, Ar-H), 7.49-7.52 (d, 1H, Ar-H), 7.77-7.80 (d, 1H, Ar-H); Anal. Calcd. For. C₁₃H₁₅ClN₆O₂S (354.82): C, 44.01; H, 4.26; Cl, 9.99; N, 23.69; S, 9.04. Found: C, 44.00; H, 4.25; Cl, 9.97; N, 23.67; S, 9.01.

3.1.2.7. Synthesis of *N*-[3,4-dihydro-4-amino-6-(*N*-(4-chlorophenyl))triazin-2-yl]benzenesulfonamide (7a).

According to general procedure II, compound **3a** reacted with 4-chloroaniline (**6**) to afford compound **7a** as a buff solid (68%); ¹H NMR (400 MHz, DMSO-*d*₆): δ 6.17 (s, 1H, NH), 6.57 (s, 1H, NH₂), 7.34-7.39 (m, 4H, Ar-H), 7.49-7.51 (d, 2H, Ar-H), 7.77-7.80 (d, 3H, Ar-H), 8.54 (s, 1H, NH); Anal. Calcd. For. C₁₅H₁₃ClN₆O₂S (376.82): C, 47.81; H, 3.48; Cl, 9.41; N, 22.30; S, 8.51. Found: C, 47.81; H, 3.48; Cl, 9.40; N, 22.30; S, 8.50.

3.1.2.8. Synthesis of *N*-[3,4-dihydro-4-amino-6-(*N*-(4-chlorophenyl)) triazin-2-yl]-4-chlorobenzenesulfonamide (7b).

According to general procedure II, compound **3b** reacted with 4-chloroaniline (**6**) to afford compound **7b** as a buff solid (71 %); mp > 350°C; IR (KBr, cm⁻¹): ν 3160 (NH), 2934 (Ar-CH), 2619 (alph. CH), 1618 (C=C), 1364, 1388, 1130 (SO₂); ¹H NMR (400 MHz, DMSO-*d*₆): δ 6.17 (s, 1H, NH), 6.57 (s, 1H, NH), 7.74 (s, 1H, NH), 7.34-7.39 (m, 4H, Ar-H), 7.49-7.51 (d, 2H, Ar-H), 7.77-7.80 (d, 2H, Ar-H), 8.54 (s, 1H, NH₂); Anal. Calcd. For. C₁₅H₁₂Cl₂N₆O₂S (411.27): C, 43.81; H, 2.94; Cl, 17.24; N, 20.43; S, 7.80. Found: C, 43.80; H, 2.94; Cl, 17.23; N, 20.42; S, 7.78.

3.2. In vitro Anti-proliferative activity

Primary anticancer assays were carried out in accordance with NCI procedures [42–46]. The compounds were applied at a single concentration, and the cell culture was then incubated for 48 hours. Sulforhodamine B (SRB), a protein-binding dye, was used to detect the endpoints. The compound's effects were displayed as a percentage growth (GP%) of the treated cells relative to the untreated cells in the control. The range of growth (%) displayed the maximum and lowest growth arising from the initial single high dosage (10⁻⁵M) sensitivity against the different cancer cell lines.

3.3. Antimicrobial Activity

Using the agar well diffusion method, the synthesized compounds were separately evaluated against a panel of Gram (+ve) and Gram (-ve) bacterial pathogens and the fungi [47]. The compounds were evaluated against fungal and bacterial strains at a concentration of 15 mg/mL. In sterilized saline equivalent to 0.5 McFarland standard solution (1.5×10^5 cfu/ml), the microbial suspension was prepared, then the turbidity of the medium was adjusted to the optical density (OD) = 0.13 at 625 nm utilizing a spectrophotometer. A sterile cotton swab should ideally be dipped into the adjusted suspension within fifteen minutes of adjusting the turbidity of the inoculum suspension, flooded over the dried agar surface, and then allowed to dry for another 15 minutes. Using a sterile borer, 6 mm-diameter wells were prepared in the solidified media. Using a micropipette, 100 μ L of the tested compound solution was added to each well. At 37 °C, the plates were then incubated. Measuring the zone of inhibition (mm) was carried out after 24 hours incubation at 30 °C for bacterial plates and 48 hours for fungal plates. The results were recorded for each tested substance as % inhibition \pm SD, and the experiment was run in triplicate. The inhibition zone s' diameters were measured in millimetres.

3.4. Cytotoxicity Assay

3.4.1. SARS-COV2

3.4.1.1. MTT Cytotoxicity Assay

To identify the half maximum cytotoxic concentration (CC_{50}), stock solutions of the tested substances were prepared in DMSO (10% in ddH₂O) and subsequently diluted to the employed concentrations using DMEM. By slightly altering the 3-(4, 5-dimethylthiazol -2-yl)-2, 5-diphenyltetrazolium bromide (MTT) technique, the cytotoxic activity of the extracts was examined in VERO-E6 cells. Briefly, the cells were seeded in 96-well plates at a density of 3×10^5 cells per ml (100 μ l /well) and then incubated for 24 hours at 37 °C in 5% carbon dioxide.

After 24 hours, the examined compounds were treated in triplicates to cells in a range of doses. The supernatant was removed twenty-four hours in advance, and cell mono-layers were then washed three times with sterile 1x PBS before being incubated for four hours at 37 degrees Celsius with MTT solution (20 μ l of a 5 mg/ml stock solution). The medium was then aspirated.

In each well, 200 μ l of acidified isopropyl alcohol (0.04 M hydrochloric acid in isopropyl alcohol = 0.073 ml hydrochloric acid in 50 ml isopropyl alcohol) was used to dissolve the produced formazan crystals. Using a multiwell-plate reader, the absorbance of formazan solutions was calculated at max λ 540 nm and

620 nm. Using a plot of cytotoxicity versus sample concentration, the concentration (CC₅₀) that indicated 50% cytotoxicity was determined.

3.4.1.2. Estimation of the inhibitory Concentration 50 % (IC₅₀)

2.4×10⁴ Vero E6 cells were seeded onto tissue culture plates (96-well), and they were then exposed to 5% carbon dioxide at 37°C for the duration of the full night.

The cell monolayers were then treated with hCoV-19/Egypt/NRC-03/2020 (Accession No. on GSAID/EPI ISL 430820) and allowed to remain there for an additional hour at ambient temperature. The cell monolayers were then covered with DMEM (100 µl) with various test drug doses.

The cells were then stained with 0.1% crystal violet in distilled water at ambient temperature for fifteen minutes, fixed with 100 µl polyoxymethylene (4%) for twenty minutes, and kept in a 5% carbon dioxide incubator at 37 °C for the ensuing 72 hours. After being fixed with 100 µl polyoxymethylene (4%) for 20 minutes, the cells were stained with 0.1% crystal violet in DH₂O at room temperature for 15 minutes. The crystal violet dye was then dissolved in 100 µl of methanol in each well (Anthos Labtec Instruments, Heerhugowaard, Netherlands) before the optical density of the colour was determined at 570 nm using an Anthos Zenyth 200rt-plate reader. The amount of a chemical required to lower the virally-induced cytopathic effect (CPE) in contrast to virus control by 50% is known as the IC₅₀.

Acknowledgments

We thank the National Cancer Institute of the USA for conducting the anticancer screening in Bethesda, Maryland.

4. References

- [1] Fischbach, M. A.; Walsh, C. T. Antibiotics for emerging pathogens. *Science*. **2009**, 325, 1089–1093. DOI: 10.1126/science.1176667.
- [2] Zhu, Y.G.; Zhao, Y.; Li, B.; Huang, C.; Zhang, S.; Yu, S.; Chen, Y.; Zhang, T.; Gillings, M. R.; Su, J. Continental-scale pollution of estuaries with antibiotic resistance genes. *Nat Microbiol*. **2017**, 2, 16270. DOI: 10.1038/nmicrobiol.2016.270.

- [3] She, W.; Ye, W.; Shi, Y.; Zhou, L.; Zhang, Z.; Chen, F.; Qian, P. Y. A novel chresdihydrochalcone from *Streptomyces chrestomyceticus* exhibiting activity against Gram-positive bacteria. *J Antibiot.* **2020**, 73(7), 429–434. DOI: 10.1038/s41429-020-0298-1.
- [4] Lu, K.; Chen, Q.; Xu, X. F.; Meng, Y.; Lin, J.; Chen, W. M. Novel benzyl phenyl sulfide derivatives as antibacterial agents against methicillin-resistant *Staphylococcus aureus*. *J Antibiot.* **2020**, 73(2), 82–90. DOI: 10.1038/s41429-019-0257-x.
- [5] Ventola, C. L. The antibiotic resistance crisis: part 1: causes and threats. *P & T: a peer-reviewed journal for formulary management.* **2015**, 40(4), 277–283.
- [6] Özgeriş, B. Design, synthesis, characterization, and biological evaluation of nicotinoyl thioureas as antimicrobial and antioxidant agents. *J Antibiot.* **2021**, 74, 233–243. DOI: 10.1038/s41429-020-00399-7.
- [7] <https://go.drugbank.com/drugs/DB05245>.
- [8] <https://go.drugbank.com/drugs/DB06147>.
- [9] <https://go.drugbank.com/drugs/DB00576>.
- [10] Gavade, S. N.; Markad, V. L.; Kodam, K. M.; Shingare, M. S.; Mane, D. V. Synthesis and biological evaluation of novel 2,4,6-triazine derivatives as antimicrobial agents. *Bioorg Med Chem Lett.* **2012**, 22(15), 5075–5077. DOI: 10.1016/j.bmcl.2012.05.111.
- [11] Solankee, A.; Kapadia, K.; Ana Cirić; Soković, M.; Doytchinova, I.; Geronikaki, A. Synthesis of some new S-triazine based chalcones and their derivatives as potent antimicrobial agents. *Eur. J. Med. Chem.* **2010**, 45(2), 510–518. DOI: 10.1016/j.ejmech.2009.10.037.
- [12] Patel, R.V.; Patel, A.B.; Kumari, P.; Chikhaliya K. H. Synthesis of novel 3-(5-sulfanyl-1,3,4-oxadiazol-2-yl)-2H-chromen-2-one condensed s-triazinyl piperazines and piperidines as antimicrobial agents. *Med Chem Res.* **2012**, 21, 3119–3132. DOI: 10.1007/s00044-011-9842-7.

- [13] Singh, U. P.; Bhat, H. R.; Gahtori, P. Antifungal activity, SAR and physicochemical correlation of some thiazole-1,3,5-triazine derivatives. *J. Mycologie Médicale*. **2012**, 22(2), 134–141. DOI: 10.1016/j.mycmed.2011.12.073.
- [14] Kumar, S.; Bhat, H. R.; Kumawat, M. K.; Singh, U. P. Design and one-pot synthesis of hybrid thiazolidin-4-one-1, 3, 5-triazines as potent antibacterial agents against human diseasecausing pathogens. *New J. Chem.* **2013**, 37, 581–584. DOI: 10.1039/C2NJ41028A.
- [15] Bhat, H. R.; Gupta, S. K.; Singh, U. P. Discovery of potent, novel antibacterial hybrid conjugates from 4-aminoquinoline and 1, 3, 5-triazine: design, synthesis and antibacterial evaluation. *RSC Adv.* **2012**, 2(33), 12690–12695. DOI: 10.1039/C2RA22353H.
- [16] Bhat, H. R.; Pandey, P. K.; Ghosh, S. K.; Singh, U. P. Development of 4-aminoquinoline-1,3,5-triazine conjugates as potent antibacterial agent through facile synthetic route. *Med Chem Res.* **2013**, 22, 5056–5065. DOI: 10.1007/s00044-013-0521-8.
- [17] Modh, R. P.; De Clercq, E.; Pannecouque, C.; Chikhaliya, K. H. Design, synthesis, antimicrobial activity and anti-HIV activity evaluation of novel hybrid quinazolinetriazine derivatives. *J. Enzyme Inhib. Med. Chem.* **2014**, 29(1), 100–108. DOI:10.3109/14756366.2012.755622.
- [18] Modh, R.P.; Patel, A. C.; Chikhaliya, K. H. Design, synthesis, antibacterial, and antifungal studies of novel 3-substituted coumarinyl-triazine derivatives. *Heterocycl. Commun.* **2013**, 19(5), 343–349. DOI: 10.1515/hc-2013-0104.
- [19] Kumar, A.; Menon, S. K. Fullerene derivatized s-triazine analogues as antimicrobial agents. *Eur. J. Med. Chem.* **2009**, 44(5), 2178–2183. DOI: 10.1016/j.ejmech.2008.10.036.
- [20] Saleh, M.; Abbott, S.; Perron, V.; Lauzon, C.; Penney, C.; Zacharie, B. Synthesis and antimicrobial activity of 2-fluorophenyl-4, 6-disubstituted [1,3,5] triazines. *Bioorg. Med. Chem. Lett.* **2010**, 20(3), 945–949. DOI: 10.1016/j.bmcl.2009.12.063.

- [21] Srinivas, K.; Srinivas, U.; Rao, V. J.; Bhanuprakash, K.; Kishore, K. H.; Murty, U. Synthesis and antibacterial activity of 2,4,6-tri substituted s-triazines. *Bioorg. Med. Chem. Lett.* **2005**, *15*(4), 1121–1123. DOI:10.1016/j.bmcl.2004.12.020.
- [22] Shanmugam, M.; Narayanan, K.; Chidambaranathan, V.; Kabilan, S. Synthesis, spectral characterization and antimicrobial studies of novel s-triazine derivatives. *Acta A Mol. Biomol. Spectrosc.* **2013**, *105*, 383–390. DOI: 10.1016/j.saa.2012.12.046.
- [23] Sun, X.; Cao, Z.; Sun, Y. *N*-chloro-alkoxy-s-triazine-based antimicrobial additives: Preparation, characterization, and antimicrobial and biofilm-controlling functions. *Ind. Eng. Chem. Res.* **2009**, *48*(2), 607–612. DOI: 10.1021/ie801110s.
- [24] Ma, X.; Tan, S. T.; Khoo, C. L.; Sim, H. M.; Chan, L. W.; Chui, W. K. Synthesis and antimicrobial activity of *N*¹-benzyl or *N*¹-benzyloxy-1,6-dihydro-1,3,5-triazine-2,4-diamines. *Bioorg. Med. Chem. Lett.* **2011**, *21*(18), 5428–5431. DOI: 10.1016/j.bmcl.2011.06.125.
- [25] Wan, Y.; Fang, G.; Chen, H.; Deng, X.; Tang, Z. Sulfonamide derivatives as potential anti-cancer agents and their SARs elucidation. *Eur. J. Med. Chem.* **2021**, *226*, 113837. DOI:10.1016/j.ejmech.2021.113837.
- [26] Elgemeie, G.H.; Mohamed-Ezzat, R.A. New Strategies Targeting Cancer Metabolism, **2022**, pp. 1-619. Amsterdam: Elsevier. ISBN: 978-0-12-821783-2. DOI:10.1016/B978-0-12-821783-2.00010-8.
- [27] Elgemeie, G.H.; Azzam, R. A.; Zaghary, W. A.; Aly, A.A.; Metwally, N .H.; Sarhan, M. O.; Abdelhafez, E. M.; Elsayed, R. E. *N*-Sulfonated-*N*-heterocycles: synthesis, chemistry, and biological applications, **2022**, pp. 1-507. Amsterdam: Elsevier. ISBN: 978-0-12-822179-2. DOI:10.1016/B978-0-12-822179-2.00004-5.

[28] Mohamed-Ezzat, R.A., Kariuki, B. M., & Elgemeie, G. H. Unexpected Products of the Reaction of Cyanoacetylhydrazones of Aryl/heteryl Ketones with Hydrazine: A New Route to Aryl/Heteryl Hydrazones, X-ray Structure, and In vitro Anti-proliferative Activity Against NCI 60-cell Line Panel, *Egyptian journal of chemistry*, **2023**, 66(13), 225-239. DOI:10.21608/ejchem.2023.197330.7682.

[29] Mohamed-Ezzat, R.A., Hashem, A.H. & Dacrory, S. Synthetic strategy towards novel composite based on substituted pyrido[2,1-*b*][1,3,4]oxadiazine-dialdehyde chitosan conjugate with antimicrobial and anticancer activities. *BMC Chemistry* **2023**, 17, 88. DOI:10.1186/s13065-023-01005-1

[30] Elgemeie, G. H.; Salah, A. M.; Abbas, N. S.; Hussein, H. A.; Mohamed, R. A. Pyrimidine non-nucleoside analogs: A direct synthesis of a novel class of *N*-substituted amino and *N*-sulfonamide derivatives of pyrimidines. *Nucleosides Nucleotides*. **2017**, 36, 213-223. DOI:10.1080/15257770.2016.1257808.

[31] Elgemeie, G. H.; Mohamed, R. A.; Hussein, H. A.; Jones, P. G. Crystal structure of *N*-(2-amino-5-cyano-4-methylsulfanyl-6-oxo-1,6-dihydropyrimidin-1-yl)-4-bromobenzene-sulfonamide dimethylformamide monosolvate, *Acta Crystallogr E Crystallogr Commun*. **2015**, 71, 1322–1324. DOI: 10.1107/S2056989015018903 .

[32] Alaoui, S.; Dufies, M.; Driowya, M.; Demange, L.; Bougrin, K.; Robert, G.; Auberger, P.; Pages, G.; Benhida, R. Synthesis and anti-cancer activities of new sulfonamides 4-substituted-triazolyl nucleosides, *Bioorg. Med. Chem. Lett.* **2017**, 27 (9), 1989-1992. DOI:10.1016/j.bmcl.2017.03.018.

[33] Elgemeie, G. H.; Mohamed, R. A. Application of Dimethyl *N*-Cyanodithioiminocarbonate in Synthesis of Fused Heterocycles and in Biological Chemistry. *Heterocycl. Commun.* **2014**, 20(6), 313-331. DOI: 10.1515/hc-2014-0156.

[34] , G. H.; , R. A. Recent Trends in Synthesis of Five- and Six-Membered Heterocycles Using Dimethyl *N*-Cyanodithioiminocarbonate. *Heterocycl. Commun.* **2014**, 20(5), 257-269. DOI: 10.1515/hc-2014-0090.

[35] Elgemeie, G. H.; Mohamed, R. A. Discovery and Synthesis of Novel Bio-Isostere of Purine Analogues Inhibiting SARS-CoV-2. *Egyptian journal of chemistry*, **2023**. DOI: 10.21608/EJCHEM.2023.196504.7681.

[36] Elgemeie, G. H.; Alkhursani, S. A.; Mohamed, R. A. New synthetic strategies for acyclic and cyclic pyrimidinethione nucleosides and their analogues, *Nucleosides Nucleotides*. **2019**, 38, 12–87. DOI: 10.1080/15257770.2018.1498511.

[37] Elgemeie, G. H.; Mohamed, R. A. Microwave chemistry: Synthesis of purine and pyrimidine nucleosides using microwave radiation. *Journal of Carbohydrate Chemistry*. **2019**, 38, 1-47. DOI: 10.1080/07328303.2018.1543430.

[38] Elgemeie, G. H.; Salah, A. M.; Abbas, N. S.; Hussein, H. A.; Mohamed, R. A. Nucleic acid components and their analogs: Design and synthesis of novel cytosine thioglycoside analogs. *Nucleosides Nucleotides*. **2017**, 36, 139-150. DOI: 10.1080/15257770.2016.1231318.

[39] Elgemeie, G. H.; Salah, A. M.; Mohamed, R. A.; Jones, P. G. Crystal structure of (*E*)-2-amino-4-methylsulfanyl-6-oxo-1-[(thiophen-2-yl)methylidene]amino-1,6-dihydropyrimidine-5-carbonitrile. *Acta Crystallogr E Crystallogr Commun*. **2015**, 71, 1319–1321. DOI: 10.1107/S205698901501885X.

[40] Mohamed-Ezzat, R. A.; Elgemeie, G. H.; Jones, P. G. Crystal structures of (*E*)-2-amino-4-methyl-sulfanyl-6-oxo-1-(1-phenyl-ethyl-idene-amino)-1,6-di-hydro-pyrimidine-5-carbo-nitrile and (*E*)-2-amino-4-methyl-sulfanyl-6-oxo-1-[1-(pyridin-2-yl)ethyl-idene-amino]-1,6-di-hydro-pyrimidine-5-carbo-nitrile. *Acta Crystallogr E Crystallogr Commun*. **2021**, 77(Pt 5), 547–550. DOI: 10.1107/S2056989021004126.

[41] Mohamed-Ezzat, R. A., Elgemeie, G. H. & Jones, P. G. (2024). An unexpected tautomer: synthesis and crystal structure of *N*-[6-amino-4-(methyl-sulfan-yl)-1,2-di-hydro-1,3,5-triazin-2-yl-idene]benzenesulfonamide. *Acta Cryst.* E80.

[42] <http://dtp.nci.nih.gov>.

- [43] Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. *Journal of the National Cancer Institute*. **1991**, 83, 757–766. DOI: 10.1093/jnci/83.11.757.
- [44] Boyd M. R., in: B.A. Teicher (Ed.), *Cancer Drug Discovery and Development*, 2, Humana Press, USA, **1997**, pp. 23-43.
- [45] Shoemaker, R. H. The NCI60 human tumor cell line anticancer drug screen, *Nat. Rev. Cancer*. **2006**, 6, 813-823. DOI: 10.1038/nrc1951.
- [46] Boyd, M. R.; Paull, K. D. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen, *Drug Dev. Res.* **1995**, 34, 91-109. DOI: 10.1002/ddr.430340203.
- [47] Scótt, A. C. Laboratory control of antimicrobial therapy. In *Practical Medical Microbiology*, 13th edn (Collee, J. G., Duguid, J. P., Fraser, A. G. & Marmion, B. P., Eds), 1989, pp. 161–81. Churchill Livingstone, Edinburgh, UK.

Funding

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Author information

Authors and Affiliations

Prof. Galal H. Elgemeie – Faculty of Science-Helwan University, Cairo, Egypt;

elgemeie@yahoo.com; galal_elgemeie@science.helwan.edu.eg

Dr. Reham A. Mohamed-Ezzat - Pharmaceutical and Drug Industries Research Institute-National Research Center, Cairo, Egypt.

reham_amgad_2010@yahoo.com; ra.mohamed-ezzat@nrc.sci.eg

Contributions

Conceptualization: Galal H. Elgemeie, Reham A. Mohamed-Ezzat; Methodology: Reham A. Mohamed-Ezzat, Galal H. Elgemeie; Writing-original draft preparation: Reham A. Mohamed-Ezzat, Galal H. Elgemeie; Writing-review and editing: Reham A. Mohamed-Ezzat, and Galal H. Elgemeie.

Corresponding authors

Correspondence to Prof. Galal H. Elgemeie

Ethics declarations

Ethics approval

The study was approved under number 15444052023 by the Medical Research Ethics Committee (MERC) federal (accurance no. : FWA 00014747).

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request

Competing interests

The authors declare no competing interests.

Conflict of Interest

The authors declare that there is no conflict to interest.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryInformation4.docx](#)